Lake Street raised the firm’s price target on Insight Molecular Diagnostics (IMDX) to $12 from $8 and keeps a Buy rating on the shares. With Insight having completed a $26M offering last week, cash on hand is now secured beyond a potential approval later this year, notes the analyst, who expects an FDA submission for GraftAssureDx in the coming weeks to be a catalyst for shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
- Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
- Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering
- Insight ‘congratulated’ STAR working group on organ health testing paper
- Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs